Benzinga Logo
QQQ
–%
DIA
–%
SPY
–%
TLT
–%
GLD
–%
BTC/USD
–%
Contribute
Sign in
Benzinga Logo
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Range
10.16 - 11.26
Vol / Avg.
164.8K/-
Div / Yield
-
52 Wk
- - -
Mkt Cap
417.3M
Payout Ratio
-
Open
11.12
P/E
-
EPS
-0.14
Shares
40.7M
Outstanding
40.7M
Total Float
-
Benzinga - Oct 12, 2021, 6:15AM
Benzinga - Oct 8, 2021, 7:53AM
Benzinga - Oct 8, 2021, 7:34AM
Benzinga - Oct 7, 2021, 5:06PM
Benzinga - Oct 7, 2021, 4:31PM
Benzinga - Oct 4, 2021, 6:07AM
Benzinga - Sep 30, 2021, 4:33PM
Benzinga - Sep 21, 2021, 6:59AM
Benzinga - Sep 20, 2021, 8:23AM
Benzinga - Sep 14, 2021, 1:21PM
Benzinga - Sep 13, 2021, 2:54PM
Benzinga - Sep 13, 2021, 9:12AM
Benzinga - Sep 13, 2021, 6:16AM
load more
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). Its product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT, and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes.

Earnings

see more
Q3 2021Est.ActualSurprise
EPS
(EXPECTED)2021-11-05
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

eFFECTOR Therapeutics Questions & Anwsers

Q

How do I buy eFFECTOR Therapeutics (EFTR) stock?

A

You can purchase shares of eFFECTOR Therapeutics (NASDAQ: EFTR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are eFFECTOR Therapeutics's (EFTR) competitors?

A

There are no as such competitors for eFFECTOR Therapeutics.

Q

What is the target price for eFFECTOR Therapeutics (EFTR) stock?

A

The latest price target for eFFECTOR Therapeutics (NASDAQ: EFTR) was reported by Credit Suisse on October 12, 2021. The analyst firm set a price target for 20.00 expecting EFTR to rise to within 12 months (a possible 94.93% upside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for eFFECTOR Therapeutics (EFTR)?

A

The stock price for eFFECTOR Therapeutics (NASDAQ: EFTR) is $10.26 last updated Fri Oct 22 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Q

Does eFFECTOR Therapeutics (EFTR) pay a dividend?

A

There are no upcoming dividends for eFFECTOR Therapeutics.

Q

When is eFFECTOR Therapeutics (NASDAQ:EFTR) reporting earnings?

A

eFFECTOR Therapeutics’s $Q3 earnings are confirmed for after-market on $November 5, 2021.

Q

Is eFFECTOR Therapeutics (EFTR) going to split?

A

There is no upcoming split for eFFECTOR Therapeutics.

Q

What sector and industry does eFFECTOR Therapeutics (EFTR) operate in?

A

eFFECTOR Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.